Browse treatments

…onstrating potential of enLIGHTEN™ to guide indication-specific immunotherapy development.…

…n select high-risk, early-stage ER +/HER2−patients treated with chemotherapy-ICI combinations.1 2 Oncolytic viruses, with their dual ability to lyse tumour c…

…mains at clinically relevant risk of recurrence and death while adjuvant immunotherapy is approved only for stages IIB-IV. The previously clinically v…

…e immunosuppressive nature of the tumor microenvironment (TME). Bacteria-mediated cancer therapy (BMCT) has emerged as a promising strategy for solid tumors but…

…ors, we assessed anti-tumor activity and survival benefit after combination therapy. To determine the requirement of a subset of immune cells (NK c…

… While significant progress has been made in the development of immunotherapy for ccRCC, there are still many unanswered questions about the …

…cally including antibodies, antibody-drug conjugates (ADC), and cell-based therapies, but none have been approved to date. We are developing a CEA-t…

…ecurrence and relapse rates among breast cancer subtypes. While chemotherapy, alone or in combination with immune checkpoint inhibitors, is …

… Despite advances such as CDK4/6 inhibitors in combination with endocrine therapy for hormone receptor-positive (HR+) breast cancer, therapeutic …

… Despite advances such as CDK4/6 inhibitors in combination with endocrine therapy for hormone receptor-positive (HR+) breast cancer, therapeutic …

…monstrated that TA-1 or anti-PD-1 inhibited tumor growth, while combination therapy led to greater tumor inhibition.Additionally, we established ad…

…res the need for improved strategies. GBM remains refractory to immunotherapy, potentially due to its immunosuppressive tumor microenvironmen…